{"id":"experimental-arm-con","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Fatigue"},{"rate":"1-5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's natural defenses to attack and destroy the cancer cells. This leads to an increase in the body's immune response against cancer.","oneSentence":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:00.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental arm (CON):","genericName":"Experimental arm (CON):","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}